Lege Artis Medicinae

[For Geriatrists]

IMRE Sándor

FEBRUARY 22, 2007

Lege Artis Medicinae - 2007;17(02)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Evidence based medicine: the experiences of the first fifteen years]

JERMENDY György

Lege Artis Medicinae

[That Place in the World... A Discussion with Zsolt Bugarszki, General Manager of Soteria Foundation and Professional Lead Ibolya Hegedűs]

GYIMESI Ágnes Andrea

Lege Artis Medicinae

[CARDIOVASCULAR EFFECTS OF SULFONYLUREAS]

NIESZNER Éva, BARANYI Éva, PRÉDA István

[Sulfonylureas, used as base therapy in type 2 diabetes, specifically block ATP-dependent potassium channels (K+ ATP). While in pancreatic beta cells these channels have an essential role in insulin release, they are also involved in cardiovascular adaptive mechanisms. Ion channels with similar morphology may have different pathophysiological effects in the human body. This raises the question, is it necessary to count with some damage to the cardiovascular protective mechanism when using sulfonylurea to induce insulin secretion. Is this indeed a relevant clinical problem today? The answer may lay in the different organ-specific effects of sulfonylureas.]

Lege Artis Medicinae

[57th Annual Meeting of the American Association for the Study of Liver Diseases]

PÉTER Zoltán

Lege Artis Medicinae

[THE ROLE OF ENZYME REPLACEMENT THERAPY IN PANCREATIC DISEASES ASSOCIATED WITH MALDIGESTION]

TAKÁCS Tamás

[The pancreas synthesizes and secretes more than 20 digestive enzymes that hydrolyze the major nutritive components, i.e., carbohydrates, fat and protein, within the lumen of the small bowel. In several pancreatic diseases the secretory capacity of the pancreas gradually decreases and the release of pancreatic juice becomes blocked resulting in the characteristic symptoms of maldigestion. Pancreas-associated maldigestion is most often caused by chronic pancreatitis, which can be diagnosed primarily by imaging beside history and clinical symptoms. There is no decisive serological test. The goal of the treatment of pancreatic insufficiency is to reduce symptoms (bloating, abdominal pain, weight loss, and, most importantly, steatorrhea) and improve digestion. One way to do this is to replace pancreatic enzymes. The efficiency of the available enzyme preparations can be increased by the improvement of lipase activity.]

All articles in the issue

Related contents